ICG
DFTX

InterOcean Capital Group’s Definium Therapeutics DFTX Stock Holding History

InterOcean Capital Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,334
Closed -$13K – 434
2022
Q2 		$13K Buy
+1,334
New +$16.9K ﹤0.01% 423

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

InterOcean Capital Group's DFTX Position: Q3 2022 in Review

InterOcean Capital Group sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,334 shares — an estimated $13K sold.

InterOcean Capital Group first reported a position in DFTX in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • InterOcean Capital Group reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • InterOcean Capital Group sold 1,334 Definium Therapeutics shares in Q3 2022, an estimated $13K.
  • InterOcean Capital Group first reported a position in Definium Therapeutics in Q2 2022 and held it in 1 quarter.
  • InterOcean Capital Group's Definium Therapeutics position peaked at $13K in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on InterOcean Capital Group's 13F filing for Q3 2022, filed 14 Nov 2022.